INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
Not for submission under 37 CFR 1.99)

Application Number		10521410
Filing Date		2005-01-18
First Named Inventor	Ullrid	n et al.
Art Unit		1642
Examiner Name	Peter	J. Reddig
Attorney Docket Numb	or	2923,679

U.S.PATENTS								Remove			
Examiner Initial*	caminer Cite No Patent Number Kind Code1		Name of Patentee or Applicant of cited Document		Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear						
	1	5468634	A1	1995-11	l-21	Liu					
If you wisl	h to ad	d additional U.S. Pate	nt citatio	n inform	ation pl	ease click the	Add button.		Add		
			U.S.P	ATENT	APPLI	CATION PUB	LICATIONS		Remove		
Examiner Initial*	Cite No Publication Number		Kind Publication Code ¹ Date		tion	of cited Decument		Releva	,Columns,Li ant Passage s Appear		
	1										
If you wis	h to ad	d additional U.S. Publ	ished Ap					d buttor			
				FOREK	SN PAT	ENT DOCUM	IENTS		Remove		
Examiner Initial*	Cite Foreign Document No Number ³		Country Code ² į		Kind Code ⁴	Publication Date	Applicant of cited		Pages,Colur where Relev Passages or Figures App	ant Relevant	т.
	1 92/17608		wo			1992-10-15	Birchmeier, Walter				
	2	2 98/06692		wo		1998-02-19	Celgene Corporation				
	3	00/76309	wo		A2	2000-12-21	Vlaams Interuniversitair Instituut Voor Biotech				

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10521410
Filing Date		2005-01-18
First Named Inventor	Ullrich	n et al.
Art Unit		1642
Examiner Name	Peter	J. Reddig
Attornov Docket Numb	or	2022 670

	4	01/78778	Wo	A1	2001-10-25	Vlaams Interuniversitair Instituut Voor Biotech.		
If you wis	h to a	dd additional Foreign P	stent Document	citation	information p	lease click the Add butto	n Add	_
			NON-PATE	NT LITI	ERATURE DO	CUMENTS	Remove	
Examiner Initials*	Cite No		nal, serial, symp	osium,	catalog, etc),	the article (when approp date, pages(s), volume-is		Τs
	1		NCER RESEARC			MPs) in breast cancer cell li ember 2001 (2001-11), page		
	2	RESEARCH AND TREA	TMENT, (OCT., 1 ICER SYMPOSIL	997) VO JM SAN	OL. 46, NO. 1, P ANTONIO, TEX	numan breast cancer.* BRE P. 91 MEETING INFO.; 201 (AS, USA DECEMBER 3-6,	TH ANNUAL SAN	
	3	DODGE ZANTEK N. ET breast cancer.* CLINICA * page 3646, right-hand	L CANCER RES	EARCH,	7/11 (3640-364	n for studying cell-ECM and 8)., November 2001 (2001- nd column *	cell-cell interactions in 11), XP001074226	
	4	JOURNAL OF BIOLOGI	CAL CHEMISTRY , MD, US, vol. 27:	, AMER	CAN SOCIETY	notaxis of vascular smooth r 7 FOR BIOCHEMISTRY AN 8 (1998-03-20), pages 7123	D MOLECULAR	
	5		2 (2002-03), - Api	ni 2002	(2002-04) XP00	ly in gastric cancer." ANTIC 8006835 * abstract * * page		
	6					cancer." CLINICAL CANCE page 366, left-hand column,		
	7		OF ONCOLOGY	, 12 (6)	819-24., June 2	otor tyrosine kinase axl in no 001 (2001-06), XP0080068 column, paragraph 1		
	8	SODIUM BUTYRATE IN	OVARIAN CARC	AMONI	CELLS" BRITIS	ASIVENESS ARE REPRES SH JOURNAL OF CANCER 1996 (1996-02-01), pages 4	, NATURE	

Application Number 10521410 Filing Date 2005-01-18 INFORMATION DISCLOSURE First Named Inventor Ullrich et al. STATEMENT BY APPLICANT 1642 Art Unit (Not for submission under 37 CFR 1.99) Evaminor Namo Peter J. Reddig Attorney Docket Number

2923-679

12	Domagala W et al. "Vimentin is preferentially expressed in human breast cardinomas with low estrogen receptor and high K-97 growth fraction? American Journal of Pathology, Vol. 136, No. 1, 1990, pages 218-227, XP008006515, ISSN: 0002-9440 Tabetact."	
11	PEDROCCH M ET AL "EXPRESSION OF CAZ-BINDING PROTEINS OF THE STUD FAMILY IN MALIGNANT HUMAN BREAST-CANCER CELL LURIS AND BIDROYS PASINES'S INTERNATIONAL JOURNAL OF CANCER, JOHN WILEY & SONS, INC, UNITED STATES, SWITZERLAND, GERMANY LINKD D01:10.1002/ILC.2910570513, vol. 57, no. 5, 1 June 1994 (1994-06-01), pages 684-690, XP001064660 ISSN. 0020-7136" the whole document.*	
10	SASKM TETAL "Crystal situature of a C-terman fragment of growth arrest-specific protein Gasts Receptor hyrotice kinses activation by lammed. Mee domans." (JURNAL OF BIOLOGIAC, CHEMISTRY, AMERICAN SOCIETY FOR BIOCHEMISTRY AND MOLECULAR BIOLOGY, INC, US LINKO DOI:10.1074/JBC M207340200, vol. 277, no. 46, 15 November 2002 (2002-11-15), pages 44164-44170, XP001168602 ISSN: 0021-9258 "abstract"	
9	ITO M ET AL "EXPRESSION OF RECEPTOR TYPE TYROSINE KINASE, AXI, AND ITS LIGAND, GAS6, IN PEDIATRIC THYROID CARCIDOMAS AROUND CHERNORY." THYROID, MARY ANN LIEBERT, NEW YORK, NY, US LINCI-DOI 10 1089/10507250225090303, vol. 12, no. 11, 1 November 2002 (2002-11-01), pages 971-975, XP008026096 ISSN 1050-7256 "abstract".	

EXAMINER SIGNATURE Examiner Signature Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04, 2 Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). 3 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. *Applicant is to place a check mark here if English language translation is attached.